TNF and psoriasis vulgaris: Similar to risankizumab, these common AEs were observed in plaque psoriasis patients assigned to active treatment arms in clinical trials of other IL-23 inhibitors, IL-17A inhibitors, and TNF inhibitors (16, 30, 33).